Breaking: Abcam to be Acquired by Danaher; Setback for NovoCure
- August 28th, 2023
- 541 views
Abcam plc (Nasdaq: ABCM) has agreed to be acquired by Danaher Corporation (NYSE: DHR) for $24.00 per share in cash.
The transaction has received unanimous approval from both Abcam's and Danaher's Boards of Directors.
In pre-market, $ABCM is trading at $23.45, up $0.09 (+0.39%), while $DHR is at $254.75, showing a decline of $0.78 (-0.31%).
In another development, NovoCure Limited (Nasdaq: NVCR) announced that its phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial evaluating Tumor Treating Fields (TTFields) alongside paclitaxel in patients with platinum-resistant ovarian cancer has not met its primary endpoint of overall survival (OS) in the final analysis.
$NVCR is currently trading at $18.00 in pre-market, down $11.77 (-39.54%) following the announcement
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
February 27th, 2026February 26th, 2026
Treasury Sanctions Nicaraguan Officials Enabling the Murillo-Ortega Dictatorship's Repression
February 26th, 2026Kansas City Storm Names Cecil Stockdale as Head Coach for 2026 NJCP Season
February 26th, 2026
Member Login